Bayer's Nexavar disappoints in breast cancer

Bayer and Amgen clocked another failed indication-expansion effort for the cancer drug Nexavar. The companies announced Friday the drug did not hit its Phase-III primary target of improving progression-free survival among patients receiving both Nexavar and chemotherapy. The RESILIENCE study focused on patients with HER2-negative breast cancer who are resistant to, or failed on, taxane therapy or who have failed on anthracycline or for whom anthracycline is not indicated.

The companies also had a setback in March when they announced Nexavar failed to hit the Phase-III target of recurrence-free survival among liver-cancer patients when used as an adjuvant therapy.

You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.